On September 1, GENSCRIPT BIO rose 3.84% in regular trading, trading at 35.32 HKD/share, with turnover of 86.13 million HKD.

On the news front, multiple brokerages recently raised their target prices following the company's strong interim results. In the first half, the company reported revenue of approximately USD 404 million, up 27.3% year-over-year, while adjusted net profit surged 203.3% to approximately USD 62.5 million, significantly beating market expectations. AIDD-related business doubled year-over-year and has maintained rapid growth for three consecutive half-year periods.

JPMorgan raised its target price to 35 HKD, maintaining an Overweight rating. Huatai Securities set its target at 36.08 HKD with a Buy rating, citing AIDD-driven life sciences revenue growth and margin expansion. BOCOM International raised its target to 32.2 HKD, projecting AIDD revenue could exceed USD 100 million in the second half. Institutions broadly view the company's expansion from gene synthesis into an integrated gene-to-protein validation platform as opening substantial medium- to long-term growth potential.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)